Erik Stomrud

List of Publications by Year
in descending order

68 papers	5,796 citations	136885 32 h-index	149623 56 g-index
75 all docs	75 docs citations	75 times ranked	5560 citing authors

#	Article	IF	Citations
1	Test–retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. Alzheimer's and Dementia, 2023, 19, 797-806.	0.4	24
2	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma $A\beta42/A\beta40$ and p–tau. Alzheimer's and Dementia, 2022, 18, 283-293.	0.4	72
3	Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer's Disease Pathology and Cognitive Decline. Biological Psychiatry, 2022, 92, 34-43.	0.7	21
4	Components of gait in people with and without mild cognitive impairment. Gait and Posture, 2022, 93, 83-89.	0.6	7
5	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurology, 2022, 79, 149.	4.5	66
6	The protective gene dose effect of the *APOE**ε2* allele on gray matter volume in cognitively unimpaired individuals. Alzheimer's and Dementia, 2022, 18, 1383-1395.	0.4	13
7	Association of CSF $A\beta_{38}$ Levels With Risk of Alzheimer Disease–Related Decline. Neurology, 2022, 98, .	1.5	16
8	Astrocytic function is associated with both amyloid-β and tau pathology in non-demented *APOE ε4* carriers. Brain Communications, 2022, 4, .	1.5	4
9	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 683-691.	1.7	8
10	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ε4, sex and age. Progress in Neurobiology, 2021, 198, 101904.	2.8	25
11	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging, 2021, 1, 114-123.	5.3	94
12	Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease. Brain, 2021, 144, 310-324.	3.7	123
13	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurology, 2021, 78, 149.	4.5	176
14	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. Translational Psychiatry, 2021, 11, 76.	2.4	78
15	Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. Scientific Reports, 2021, 11, 1965.	1.6	28
16	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nature Medicine, 2021, 27, 1034-1042.	15.2	236
17	Soluble P–tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Molecular Medicine, 2021, 13, e14022.	3.3	90
18	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain, 2021, 144, 2826-2836.	3.7	65

#	Article	IF	Citations
19	Tau PET correlates with different Alzheimer's disease–related features compared to CSF and plasma p–tau biomarkers. EMBO Molecular Medicine, 2021, 13, e14398.	3.3	58
20	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology, 2021, 97, e1681-e1694.	1.5	60
21	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	6
22	Unravelling drivers of age–and beta–amyloid–related neurodegeneration in medial temporal lobe atrophy in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
23	Biomarker driven enrichment strategies for tau pathology in AD clinical trials. Alzheimer's and Dementia, 2021, 17, .	0.4	0
24	Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
25	Lower cognitive resilience against brain atrophy in cognitively unimpaired elderly is partly explained by Alzheimer's disease pathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
26	Amyloid–β accumulation is independently related to executive function in cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
27	Associations between longitudinal neuropsychiatric symptoms and biomarkers of beta–amyloid, tau, neurodegeneration, and cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	1
28	The association between diet in mid–life and dementia incidence over a 20–year period. Alzheimer's and Dementia, 2021, 17, .	0.4	0
29	Potential drivers of age–and beta–amyloid–related neurodegeneration in early and late Alzheimer's Disease regions in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
30	Prediction of future Alzheimer's disease dementia using plasma phospho–tau combined with other accessible measures. Alzheimer's and Dementia, 2021, 17, .	0.4	2
31	Apathy and anxiety are early markers of Alzheimer's disease. Neurobiology of Aging, 2020, 85, 74-82.	1.5	103
32	Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain, 2020, 143, 3234-3241.	3.7	150
33	Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load. Neurology, 2020, 95, e2834-e2844.	1.5	14
34	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2020, 324, 772.	3.8	640
35	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. Neurobiology of Aging, 2020, 95, 143-153.	1.5	34
36	Phospho–tau217 and phospho–tau181 in plasma and CSF as biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037520.	0.4	2

#	Article	IF	Citations
37	Mild behavioral impairment is predictive of tau deposition in the earliest stages of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042595.	0.4	6
38	A costâ€consequence analysis of early detection of AD in the MOPEAD project â€" A project within the EU research agenda IMIâ€2. Alzheimer's and Dementia, 2020, 16, e042774.	0.4	0
39	Improved performance of Elecsys CSF Abeta measurement achieved using the simple, unified routineâ€use protocol for CSF collection. Alzheimer's and Dementia, 2020, 16, e047394.	0.4	0
40	Analytical characteristics of the updated elecsys Abeta42 Gen 2 assay, including comparisons with the Gen 1 assay. Alzheimer's and Dementia, 2020, 16, e047517.	0.4	0
41	CDH6 and HAGH protein levels in plasma associate with Alzheimerâ€™s disease in APOE Îµ4 carriers. Scientific Reports, 2020, 10, 8233.	1.6	17
42	The implications of different approaches to define AT(N) in Alzheimer disease. Neurology, 2020, 94, e2233-e2244.	1.5	80
43	AÎ² deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimerâ€™s disease. Science Advances, 2020, 6, eaaz2387.	4.7	202
44	Preâ€analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12137.	1.2	20
45	Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology, 2019, 93, e322-e333.	1.5	96
46	Staging **Î²**-Amyloid Pathology With Amyloid Positron Emission Tomography. JAMA Neurology, 2019, 76, 1319.	4.5	149
47	Towards a unified protocol for handling of CSF before Î²-amyloid measurements. Alzheimer's Research and Therapy, 2019, 11, 63.	3.0	38
48	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Diseaseâ€"Related Î²-Amyloid Status. JAMA Neurology, 2019, 76, 1060.	4.5	282
49	DTâ€01â€04: DIAGNOSTIC PERFORMANCE OF [18F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDERâ€2 STUDY. Alzheimer's and Dementia, 2019, 15, P1485.	0.4	0
50	Brain myoinositol as a potential marker of amyloid-related pathology. Neurology, 2019, 92, e395-e405.	1.5	30
51	Accurate risk estimation of Î²â€amyloid positivity to identify prodromal Alzheimer's disease: Crossâ€validation study of practical algorithms. Alzheimer's and Dementia, 2019, 15, 194-204.	0.4	49
52	CSF biomarkers of Alzheimer's disease concord with amyloidâ€Î² PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer's and Dementia, 2018, 14, 1470-1481.	0.4	468
53	Altered structural network organization in cognitively normal individuals with amyloid pathology. Neurobiology of Aging, 2018, 64, 15-24.	1.5	30
54	Increased midlife triglycerides predict brain Î²-amyloid and tau pathology 20 years later. Neurology, 2018, 90, e73-e81.	1.5	76

#	Article	IF	Citations
55	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, 2018, 91, e867-e877.	1.5	207
56	Effects of APOE Îµ4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. Neurobiology of Aging, 2018, 71, 81-90.	1.5	15
57	Greater tau load and reduced cortical thickness in APOE Îµ4-negative Alzheimerâ€™s disease: a cohort study. Alzheimer's Research and Therapy, 2018, 10, 77.	3.0	56
58	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. Hippocampus, 2017, 27, 653-667.	0.9	20
59	Earliest accumulation of Î²-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nature Communications, 2017, 8, 1214.	5.8	596
60	Psychometric testing of a Swedish version of the Apathy Evaluation Scale. Nordic Journal of Psychiatry, 2017, 71, 477-484.	0.7	5
61	Plasma tau in Alzheimer disease. Neurology, 2016, 87, 1827-1835.	1.5	371
62	Increased amyloidogenic APP processing in APOE É›4-negative individuals with cerebral Î²-amyloidosis. Nature Communications, 2016, 7, 10918.	5.8	48
63	<scp>CSF</scp> Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology, 2016, 3, 154-165.	1.7	329
64	Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9â€year study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 403-411.	1.2	26
65	Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-Sectional Cohort Study Evaluating the Effect of Arterial Stiffness. Cerebrovascular Diseases Extra, 2015, 5, 41-51.	0.5	33
66	Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults. Archives of Neurology, 2010, 67, 217-23.	4.9	99
67	Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease. PLoS ONE, 2009, 4, e6294.	1.1	79
68	Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly. Dementia and Geriatric Cognitive Disorders, 2007, 24, 118-124.	0.7	148